KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Issued (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Shares Issued for 15 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 24.43% to $8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.6 million, a 152.32% increase, with the full-year FY2025 number at $37.6 million, up 152.32% from a year prior.
  • Shares Issued was $8.6 million for Q4 2025 at Supernus Pharmaceuticals, down from $23.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $23.7 million in Q3 2025 to a low of $524000.0 in Q3 2021.
  • A 5-year average of $3.9 million and a median of $2.4 million in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 6921.88% in 2021, then tumbled 88.54% in 2023.
  • Supernus Pharmaceuticals' Shares Issued stood at $1.6 million in 2021, then surged by 79.62% to $2.8 million in 2022, then crashed by 61.4% to $1.1 million in 2023, then surged by 529.76% to $6.9 million in 2024, then increased by 24.43% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Shares Issued are $8.6 million (Q4 2025), $23.7 million (Q3 2025), and $3.3 million (Q2 2025).